SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
(Amendment No. 1)
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
May 3, 2012 Date of report (Date of earliest event reported)
(Exact name of Registrant as specified in its charter)
5885 Hollis Street, Suite 100, Emeryville, CA 94608
(Address of principal executive offices) (Zip Code)
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2 below):
Amyris, Inc. (the Company) is filing this Amendment No. 1 on Form 8K/A to the Companys Current Report on Form 8K dated May 3, 2012, which was filed on May 7, 2012 (the 8-K), in order to correct a statement in the 8-K regarding beneficial ownership by TPG Biotechnology Partners II, L.P. of Company securities.
As previously disclosed in the 8-K, Dr. Duyk was appointed to the Companys Board of Directors as of May 3, 2012. Dr. Duyk is a partner of TPG Biotech, an affiliate of TPG Biotechnology Partners II, L.P. TPG Biotechnology Partners II, L.P. holds 3,262,450 shares of the Companys Common Stock, which, as April 27, 2012, represented more than 5% of the Companys outstanding Common Stock.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.